Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
出版年份 2017 全文链接
标题
Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
作者
关键词
-
出版物
Therapeutic Advances in Medical Oncology
Volume 9, Issue 10, Pages 627-636
出版商
SAGE Publications
发表日期
2017-08-02
DOI
10.1177/1758834017724314
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?
- (2017) Sebastiano Buti et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).
- (2017) Andrea Borghese Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) B. Escudier et al. ANNALS OF ONCOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
- (2016) Steven A. Lacy et al. CLINICAL PHARMACOKINETICS
- The ‘nivolution’ in renal cell carcinoma: behind the scenes of clinical trials
- (2016) Sebastiano Buti et al. Future Oncology
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
- (2016) Witold Wiecek et al. PLoS One
- Combination therapy in kidney cancer: the next revolution?
- (2015) Sebastiano Buti et al. LANCET ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Renal-Cell Cancer — Targeting an Immune Checkpoint or Multiple Kinases
- (2015) David I. Quinn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma
- (2015) G. de Velasco et al. Cancer Immunology Research
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
- (2014) L. Albiges et al. CLINICAL CANCER RESEARCH
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon
- (2009) Elizabeth R. Plimack et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started